CytoDyn Inc.

CytoDyn Inc. is a clinical-stage biotechnology company focused on the clinical development of innovative treatments for multiple therapeutic indications. The company's primary product candidate is leronlimab (also known as PRO 140), a novel humanized monoclonal antibody that targets the C-C chemokine receptor type 5 ("CCR5"). CytoDyn Inc. was originally incorporated on May 2, 2002, in Colorado under the name RexRay Corporation, and reincorporated in Delaware on August 27, 2015. The preclinical and early clinical development of PRO 140 was conducted by Progenics until 2011, and CytoDyn Inc. acquired the asset from Progenics in October 2012. In November 2018, the United States Adopted Names Council officially adopted "leronlimab" as the nonproprietary name for PRO 140. The company's current business strategy involves continuing the clinical development of leronlimab, which is being studied for its potential in solid-tumor oncology. Leronlimab targets CCR5, a receptor that is increasingly recognized for its involvement in tumor progression, metastasis, and immune regulation. This provides CytoDyn Inc. with the opportunity to explore a potentially differentiated therapeutic approach across multiple solid tumor indications. The company's principal business office is located at 1111 Main Street, Suite 660, Vancouver, Washington 98660. The consolidated financial statements include the accounts of CytoDyn Inc. and its wholly owned subsidiary, CytoDyn Operations Inc.